byiShook Opinion
Mar 11, 2025 - 12:50
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug. The post Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug appeared first on Investor's Business Daily.
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
The post Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug appeared first on Investor's Business Daily.